Moores; Sheri

Patent Applications and Registrations

Patent applications and USPTO patent grants for Moores; Sheri.The latest application filed is for "treatment of cancers lacking egfr- activating mutations".

Company Profile

6.7.20

Moores; Sheri - Wayne PA
Moores; Sheri - Phoenixville PA
Moores; Sheri - Spring House PA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Treatment of Cancers Lacking EGFR- Activating Mutations App 20220298248 - Henley; Benjamin ; et al.	2022-09-22
Treatment of Non-Small Cell Lung Cancer with EGFR Mutations App 20220064306 - Knoblauch; Roland ; et al.	2022-03-03
Bispecific EGFR/C-Met Antibodies App 20210395373 - Chiu; Mark ; et al.	2021-12-23
Treatment of Patients Having c-Met Exon 14 Skipping Mutations App 20210253717 - Knoblauch; Roland ; et al.	2021-08-19
EGFR and C-Met Fibronectin Type III Domain Binding Molecules App 20210206825 - Anderson; Mark ; et al.	2021-07-08
EGFR and c-Met fibronectin type III domain binding molecules Grant 10,954,284 - Anderson , et al. March 23, 2	2021-03-23
Combination Therapies With Bispecific Anti-EGFR/c-Met Antibodies and Third Generation EGFR Tyrosine Kinase Inhibitors App 20210017285 - Laquerre; Sylvie ; et al.	2021-01-21
Cysteine Engineered Fibronectin Type Iii Domain Binding Molecules App 20200325210 - Anderson; Mark ; et al.	2020-10-15
Combination Therapies and Patient Stratification with Bispecific Anti-EGFR/c-Met Antibodies App 20200270351 - Moores; Sheri ; et al.	2020-08-27
Cysteine engineered fibronectin type III domain binding molecules Grant 10,662,235 - Anderson , et al.	2020-05-26
Bispecific EGFR/C-Met Antibodies App 20200087407 - Chiu; Mark ; et al.	2020-03-19
Bispecific EGFR/C-Met Antibodies App 20180258173 - Chiu; Mark ; et al.	2018-09-13
Cysteine Engineered Fibronectin Type III Domain Binding Molecules App 20170362301 - Anderson; Mark ; et al.	2017-12-21
EGFR and C-Met Fibronectin Type III Domain Binding Molecules App 20170305997 - Anderson; Mark ; et al.	2017-10-26
Bispecific EGFR/C-Met Antibodies App 20170275367 - Chiu; Mark ; et al.	2017-09-28
EGFR and C-Met fibronectin type III domain binding molecules Grant 9,725,497 - Anderson , et al. August 8, 2	2017-08-08
EGFR and c-Met fibronectin type III domain binding molecules Grant 9,695,228 - Mark , et al. July 4, 2	2017-07-04
Bispecific EGFR/c-Met antibodies Grant 9,695,242 - Chiu , et al. July 4, 2	2017-07-04
Bispecific EGFR/C-Met Antibodies App 20170101475 - Chiu; Mark ; et al.	2017-04-13
Bispecific EGFR/c-Met antibodies Grant 9,593,164 - Chiu , et al. March 14, 2	2017-03-14
Bispecific EGFR/c-Met antibodies Grant 9,580,508 - Chiu , et al. February 28, 2	2017-02-28
Human Autotaxin Antibodies and Methods of Use App 20150087812 - Chi; Ellen ; et al.	2015-03-26
Bispecific EGFR/C-Met Antibodies App 20140255408 - Chiu; Mark ; et al.	2014-09-11
Egfr And C-met Fibronectin Type Iii Domain Binding Molecules App 20140155325 - Mark; Anderson ; et al.	2014-06-05
Egfr And C-met Fibronectin Type Iii Domain Binding Molecules App 20140155326 - Mark; Anderson ; et al.	2014-06-05
Bispecific EGFR/C-Met Antibodies App 20140141000 - Chiu; Mark ; et al.	2014-05-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.